Momentum Life Sciences announced a strategic investment from Parthenon Capital. Financial terms of the transaction were not disclosed. Momentum is a commercialization platform offering patient- and provider-facing solutions that support therapy initiation and adherence for specialty therapies.
Parthenon Capital is a growth-oriented private equity firm with experience supporting healthcare solutions and technology companies. Following the investment, Momentum’s existing leadership team will continue as significant shareholders in the company.
The investment will provide Momentum with strategic resources and capital to accelerate its growth strategy. Momentum also plans to pursue strategic acquisitions that support its mission of helping patients start and stay on specialty therapies.
The company said the investment addresses a persistent challenge for pharmaceutical and biotechnology manufacturers, patients, and providers: improving access, initiation, and adherence for specialty therapies.
Momentum’s platform supports patient and provider engagement after the therapy decision has been made.
The company uses technology-enabled and data-driven human connections to support behavior change and improve adherence.
Parthenon said therapy adoption, initiation, and adherence remain acute and underserved challenges for life sciences organizations.
The firm also noted that as therapies become more specialized, navigating behavioral, access, financial, and operational barriers has become increasingly important.
Momentum Life Sciences is a provider of patient support solutions focused on improving adherence and helping providers ensure effective patient starts. The firm invests in growth companies across service and technology industries, with particular expertise in financial and insurance services, healthcare, and technology services.
Support: William Blair served as financial advisor to Momentum. Cooley served as legal counsel to Momentum. Kirkland & Ellis served as legal counsel to Parthenon.
KEY QUOTES:
“This is a defining moment for Momentum and the clients, patients, and providers we serve. Partnering with Parthenon provides us with additional resources and an aligned strategic partner to continue to strengthen our platform, deepen our capabilities, and take on a greater role in creating better experiences and outcomes for clients, patients, and providers, which sits at the heart of everything we do.”
Andi Heslin Smiley, President and CEO of Momentum Life Sciences
“Therapy adoption, initiation, and adherence are some of the most acute and underserved challenges facing life sciences organizations today. As therapies have become more specialized, navigating behavioral, access, financial, and operational barriers to treatment has become increasingly important. Momentum has built a differentiated platform to address these pain points, and we see a compelling opportunity to expand the Company’s presence across the commercialization ecosystem.”
Dan Killeen, Partner at Parthenon Capital
“Momentum has built something rare: a deeply trusted clinical and human-centered platform that has proven to not only improve the patient and provider experience but also drive tangible and consistent commercial impacts for clients. We see tremendous potential in continuing the Company’s mission and expanding the role Momentum plays in supporting life sciences organizations, providers, and patients along the specialty therapy journey. We are excited to support Andi and the team as Momentum enters this next chapter of growth.”
Patrick Hunt, Principal at Parthenon Capital
